Birch Hill Investment Advisors LLC decreased its stake in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Free Report) by 19.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,676 shares of the company's stock after selling 59,324 shares during the quarter. Birch Hill Investment Advisors LLC owned about 1.01% of PureTech Health worth $4,186,000 at the end of the most recent reporting period.
Separately, Pentwater Capital Management LP increased its stake in PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock valued at $664,000 after purchasing an additional 9,449 shares in the last quarter. 0.04% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a "sell (d)" rating on shares of PureTech Health in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of "Sell".
Read Our Latest Research Report on PRTC
PureTech Health Trading Up 0.0%
NASDAQ:PRTC opened at $18.18 on Wednesday. PureTech Health PLC Sponsored ADR has a 1-year low of $13.30 and a 1-year high of $24.99. The company's fifty day moving average price is $17.53 and its 200-day moving average price is $17.63.
About PureTech Health
(
Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
